Spectral's EAA debuts in Russia
This article was originally published in Clinica
Continuing its expansion into new global markets, Canadian IVD company Spectral Diagnostics is to see its endotoxin activity assay (EAA) distributed exclusively in Russia by BB Medical. The deal is a result of an agreement in May between Spectral and Toray Medical – a subsidiary of Japanese chemicals group Toray Industries – in which the Toronto-based company would be granted access to Toray's distributors in various international territories. Aside from Russia, these countries include China, India and Canada. The distributors will sell the EAA as a standalone product, and in combination with Toray's blood purification device, which removes endotoxin from the bloodstream. The EAA is the only FDA-cleared assay for the measurement of endotoxin, the most common mediator of sepsis, and is used to assess a patient's risk of developing the severe form of the disease. Spectral president and CEO Dr Paul Walker indicated that severalmore distribution agreements in new geographic territories would follow.